New NHS guidance recommends annual checks for women with Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly Polycystic Ovary Syndrome. The condition affects 1 in 8 women and is linked to infertility, irregular periods, and risks like diabetes and heart disease. NICE urges faster diagnosis and better monitoring.
New NHS guidance suggests investigating up to 4 million women with irregular periods for Polyendocrine Metabolic Ovarian Syndrome (PMOS), previously known as Polycystic Ovarian Syndrome. The condition, affecting up to 13% of reproductive-age women, is often underdiagnosed and inconsistently managed. The guidance covers a wider demographic and emphasizes annual reviews for monitoring symptoms and associated health risks.
Polyend's Endless is a $299 programmable guitar pedal that uses AI agents to turn text prompts into custom effects. While it offers a user-friendly way to create unique sounds, iterating and firmware quirks can be frustrating, and it doesn't offer the control of higher-priced alternatives.
Polycystic Ovary Syndrome (PCOS), affecting over 3 million UK women, is renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its complex hormonal nature, aiming to improve diagnoses and treatment.
Polycystic ovary syndrome (PCOS) has been renamed to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its systemic impact beyond ovarian cysts, affecting nearly one in eight women globally
